Stockscreener 앱 받기
7.79
2.87%
-0.23
시간 외 거래:
7.75
-0.04
-0.51%
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders - BioBuzz
BioCryst Pharmaceuticals stock fell 1.85 percent on October 6 - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals Inc (BO1.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BioCryst Pharmaceuticals stock gets a new science board - AD HOC NEWS
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board - www.marketscreener.com
BioCryst forms scientific advisory board for R&D strategy By Investing.com - Investing.com India
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
JPMorgan raises target for BioCryst Pharmaceuticals stock - AD HOC NEWS
BioCryst Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by JP Morgan - Moomoo
BCRX Maintained by JP Morgan -- Price Target Raised to $13.00 - GuruFocus
J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Claude AI Just Bought These 2 Pharma Stocks - finance.yahoo.com
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - finance.yahoo.com
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - AD HOC NEWS
Biopharma Stock With Layers of Technical Support in Place - Yahoo Finance
Biopharma Stock With Layers of Technical Support in Place - Schaeffer's Investment Research
BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus
RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Yahoo Finance
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - Yahoo Finance
BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com India
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
C5 inhibitors disclosed in Biocryst patents - BioWorld News
BioCryst to Present at Upcoming Investor Conference - marketscreener.com
BioCryst to Present at Upcoming Investor Conference - GlobeNewswire
BioCryst to Present at Upcoming Investor Conference - Yahoo Finance
Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan
BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de
2.82%
2.38%
자본화:
|
볼륨(24시간):